Care with allergen immunotherapy for allergic respiratory diseases in Germany-Predictors and deficits.
epidemiology
immunotherapy and tolerance induction
prevention
regulatory aspects
rhinitis
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
27
03
2022
received:
14
12
2021
accepted:
13
04
2022
pubmed:
8
5
2022
medline:
15
12
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Allergen immunotherapy (AIT) represents the only possibility of causal therapy for allergic respiratory diseases. Although the prevailing high prevalence of allergic diseases and restrictions in the daily lives of patients, AIT is offered to a suboptimal number of patients in Germany. Insured patients with documented allergic respiratory disease of one of the largest statutory health insurances in Germany, 'DAK-Gesundheit', were contacted by postal mail and asked to participate in the study. In case of written consent, primary and secondary data of patients were collected and analysed. Patient characteristics, predictors of being offered AIT, predictors of performing AIT and guideline-compliant care were analysed. 2505 subjects were included in the VerSITA study. Allergy to tree pollen and native speaking were identified as predictors, which increase the probability of being offered AIT. The probability was significantly decreased by the characteristics allergic rhinitis only, allergic asthma only, age in years, non-German citizenship, no graduation and lower secondary qualification. Significant positive predictors for an AIT to be actually performed were: Allergy to tree pollen and male sex. Predictors that decrease the likelihood that AIT is performed were: only allergic asthma, current smoker, former smoker, age and non-German citizenship. Furthermore, it was possible to identify characteristics in which guideline-compliant patients differed significantly from the rest of the study population. Based on statutory health insurance data and patient survey data, the VerSITA study provides a broad and in-depth overview of the care situation with regard to AIT in Germany and identifies deficits.
Sections du résumé
BACKGROUND
Allergen immunotherapy (AIT) represents the only possibility of causal therapy for allergic respiratory diseases. Although the prevailing high prevalence of allergic diseases and restrictions in the daily lives of patients, AIT is offered to a suboptimal number of patients in Germany.
METHODS
Insured patients with documented allergic respiratory disease of one of the largest statutory health insurances in Germany, 'DAK-Gesundheit', were contacted by postal mail and asked to participate in the study. In case of written consent, primary and secondary data of patients were collected and analysed. Patient characteristics, predictors of being offered AIT, predictors of performing AIT and guideline-compliant care were analysed.
RESULTS
2505 subjects were included in the VerSITA study. Allergy to tree pollen and native speaking were identified as predictors, which increase the probability of being offered AIT. The probability was significantly decreased by the characteristics allergic rhinitis only, allergic asthma only, age in years, non-German citizenship, no graduation and lower secondary qualification. Significant positive predictors for an AIT to be actually performed were: Allergy to tree pollen and male sex. Predictors that decrease the likelihood that AIT is performed were: only allergic asthma, current smoker, former smoker, age and non-German citizenship. Furthermore, it was possible to identify characteristics in which guideline-compliant patients differed significantly from the rest of the study population.
CONCLUSIONS
Based on statutory health insurance data and patient survey data, the VerSITA study provides a broad and in-depth overview of the care situation with regard to AIT in Germany and identifies deficits.
Substances chimiques
Allergens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1422-1431Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Bousquet J, Khaltaev N, Cruz A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA[2]LEN and AllerGen). Allergy. 2008;63(86):8-160. doi:10.1111/j.1398-9995.2007.01620.x
Muraro A, Robert G, Halken S, et al. EAACI guidelines on allergen immunotherapy: executive statement. Allergy. 2018;73(4):739-743. doi:10.1111/all.13420
Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556-568
Pfaar O, Angier E, Muraro A, Halken S, Roberts G. Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. Allergy. 2020;75(9):2411-2414. doi:10.1111/all.14270
Klimek L, Brehler R, Hamelmann E, et al. Evolution of subcutaneous allergen immunotherapy (part 1): from first developments to mechanism-driven therapy concepts. Allergo J Int. 2019;28(3):78-95. doi:10.1007/s40629-019-0092-4
Klimek L, Brehler R, Hamelmann E, et al. Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations. Allergo J Int. 2019;28(4):107-119. doi:10.1007/s40629-019-0097-z
Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on Allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2017;73(4):765-779. doi:10.1111/all.13317
Pfaar O, Bachert C, Buffe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int. 2014;23:282-319. doi:10.1007/s40629-014-0032-2
Bachert C, Borchard U, Wedi B, et al. Leitlinie der DGAI zur allergischen Rhinokonjunktivitis. Allergo J. 2003;12:182-194.
Schulz M, Martin E, Dalhoff K, et al. Nationale Versorgungsleitlinie Asthma. 4. Auflage. AWMF online. doi:10.6101/AZQ/000469
Romano M, James S, Farrington E, et al. The impact of perennial allergic rhinitis with/without allergic asthma on sleep, work and activity level. Allergy Asthma Clin Immunol. 2019;15(81):1-10. doi:10.1186/s13223-019-0391-9
Distler A, Pappelendam D. 13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation. Allergo J Int 2015;24(8):294-302. doi:10.1007/s40629-015-0084-y
Rabe U, Altengarten J, Benke E, et al. Long-term efficacy of specific subcutaneous, short-term MPL adjuvant immunotherapy over three treatment and three follow-up years, as measured by quality of life. Allergo J Int. 2017;26(5):147-154. doi:10.1007/s40629-017-0029-8
Biermann J, Merk H, Wehrmann W, et al. Allergic disorders of the respiratory tract-findings from a large patient sample in the German statutory health insurancesystem. Allergo J. 2013;22:366-373. doi:10.1007/s15007-013-0350-6
Weschenfelder A-K, Wasem J, Biermann J. Versorgung von Patienten mit allergischer Rhinitis - eine Analyse von Routinedaten einer gesetzlichen Krankenversicherung. Allergologie. 2015;38(5):252-259. doi:10.5414/ALX01749
Weschenfelder A-K, Klimek L, Mülleneisen N, et al. Course of respiratory allergy by treatment strategy based on German routine data. Allergo J Int. 2017;26(6):195-203. doi:10.1007/s40629-017-0027-x
Valbert F, Neusser S, Riederer C, et al. Health care situation in patients with allergic respiratory diseases with special focus on specific immunotherapy. Allergo J Int. 2021;30(1):39-45. doi:10.1007/s40629-020-00149-z
Haftenberger M, Laußmann D, Ellert U, et al. Prävalenz von Sensibilsierungen gegen Inhalations- und Nahrungsmittelallergene. Bundesgesundheitsblatt. 2013;56:687-697. doi:10.1007/s00103-012-1658-1
Razum O, Geiger I, Zeeb H, et al. Gesundheitsversorgung von Migranten. Deutsches Ärzteblatt. 2004;101(43):A2882-A2887.
Ryan D, Gerth van Wijk R, Angier E, et al. Challenges in the implementation of the EAACI AIT guidelines: a situational analysis of current provision of allergen immunotherapy. Allergy. 2017;73(4):827-836. doi:10.1111/ALL:13264
Hellings PW, Pugin B, Mariën G, et al. Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement. Clin Transl Allergy. 2019;9(1):1-7. doi:10.1186/s13601-019-0243-1
Brehler R, Klimek L, Vogelberg C, Werfel T, Pfaar O, Hamelmann E. Evidence vs. efficacy in allergen-specific immunotherapy: considerations using the example of tradable products in Germany. Allergo J Int. 2016;25(2):38-43. doi:10.1007/s40629-016-0096-2